Active, Not Recruiting
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
NCT02879695
- Conditions
- Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +22 more
- Locations
-
- Yale University New Haven, Connecticut, United States
- University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States